login
  Password reminder
NeuroNews
Contact the editor Visit NeuroNews Twitter feed Visit NeuroNews Facebook page
 

Study says that there is no evidence to support concerns that neurodegenerative disease-associated proteins transmit Alzheimer’s or Parkinson’s disease


Tuesday, 12 Feb 2013 11:46
Pathological deposits of Alzheimer's disease and Parkinson's disease-associated proteins
Pathological deposits of Alzheimer's disease and Parkinson's disease-associated proteins

On 4 February 2013, in a study published online in JAMA Neurology, by David Irwin, University of Pennsylvania Perelman School of Medicine, Philadelphia, USA, and colleagues, reported a first group of recipients of cadaver-derived human growth hormone (c-hGH) who do not appear to be at increased risk for Alzheimer and Parkinson disease despite their likely exposure to neurodegenerative disease-associated proteins and elevated risk of infectious prion protein-related disease.


Irwin et al looked for evidence for human-to-human transmission of Alzheimer disease, Parkinson disease, and related neurodegenerative disease-associated proteins in c-hGH recipients. (Image: A=AB, the main component of Alzheimer’s disease-associated plaques, B=Tau, the main component of Alzheimer’s disease-associated tangles, C=Alpha-synuclein, the main component of Lewy bodies in Parkinson’s disease).

The study included 34 routine autopsy patients and a group of c-hGH recipients in the National Hormone and Pituitary Program (NHPP). No cases of Alzheimer’s disease or Parkinson’s disease were identified, according to the study results.

“We found no evidence to support concerns that neurodegenerative disease-associated proteins underlying Alzheimer’s disease and Parkinson’s disease transmit disease in humans despite evidence of their cell-to-cell transmission in model systems of these disorders. Further monitoring is required to confirm these conclusions,” the authors added.




Add New Comment

Related Items


Most popular


MR CLEAN: expert opinion
Tuesday, 18 Nov 2014
Since the first presentation of data at the World Stroke Congress, the MR CLEAN trial has sent a ripple across the entire neurointerventional arena, raising questions about the future of stroke ... MR CLEAN: expert opinion

First patient treated in US pivotal trial evaluating cerebral protection during TAVI
Thursday, 09 Oct 2014
The randomised controlled SENTINEL Trial is the first in the USA to study capture and removal of debris released during TAVI that may otherwise be the source of stroke. First patient treated in US pivotal trial evaluating cerebral protection during TAVI

New Envoy catheters launched
Saturday, 11 Oct 2014
Codman Neuro has announced the Europe, Middle East and Africa launch of the Envoy DA XB Distal Access Guiding Catheter and the 7F Envoy Guiding Catheter for neurovascular procedures. New Envoy catheters launched

Features


The changing face of traumatic brain injury: Life beyond the guidelines
Tuesday, 18 Nov 2014
András Büki and Andrew Maas write that despite considerable efforts both in basic and clinical research, there has not been a major breakthrough in the care of the head injured in the last three ... The changing face of traumatic brain injury: Life beyond the guidelines

Neuro-oncologic treatment for glioblastoma
Monday, 21 Jul 2014
Malignant gliomas are the most common type of primary malignant brain tumour, accounting for 80% of patients and an annual incidence of 5.26 per 100,000 population, or 17,000 new cases diagnosed per ... Neuro-oncologic treatment for glioblastoma

Profiles


Vladimír Beneš Jr
Tuesday, 30 Sep 2014
Vladimír Beneš Jr is professor and chair at the First Medical School, Charles University, P... Vladimír Beneš Jr

Mauricio Castillo
Monday, 14 Jul 2014
Mauricio Castillo is a professor of Radiology and chief, Division of Neuroradiology, University of N... Mauricio Castillo

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions